Compare · CTMX vs XNCR
CTMX vs XNCR
Side-by-side comparison of CytomX Therapeutics Inc. (CTMX) and Xencor Inc. (XNCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTMX and XNCR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- XNCR is the larger of the two at $1.11B, about 1.4x CTMX ($796.8M).
- Over the past year, CTMX is up 52.0% and XNCR is up 77.0% - XNCR leads by 25.1 points.
- XNCR has been more active in the news (10 items in the past 4 weeks vs 9 for CTMX).
- Both have 22 recent analyst ratings on file.
- Company
- CytomX Therapeutics Inc.
- Xencor Inc.
- Price
- $3.64-1.49%
- $14.96-0.07%
- Market cap
- $796.8M
- $1.11B
- 1M return
- +22.56%
- +23.84%
- 1Y return
- +51.98%
- +77.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2013
- News (4w)
- 9
- 10
- Recent ratings
- 22
- 22
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Xencor Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., Janssen Biotech, Inc.; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Latest CTMX
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- SEC Form 4 filed by Director Su Zhen
- SEC Form 8-K filed by CytomX Therapeutics Inc.
- SEC Form 4 filed by Director Young Matthew P.
- SEC Form 4 filed by Director Mohindru Mani
- SEC Form 4 filed by Director Meyers James R
- SEC Form 4 filed by Director Gilbert Halley E
- SEC Form 4 filed by Director Ashworth Alan
- SEC Form 4 filed by Director Jones Elaine V
- Chief Financial Officer Ogden Christopher sold $4,953 worth of shares (1,624 units at $3.05), decreasing direct ownership by 0.55% to 295,324 units (SEC Form 4) to satisfy withholding obligation
Latest XNCR
- Director Feigal Ellen was granted 10,302 shares, increasing direct ownership by 83% to 22,642 units (SEC Form 4)
- Director Gorman Kevin Charles was granted 10,302 shares, increasing direct ownership by 91% to 21,680 units (SEC Form 4)
- Director Gustafson Kurt A was granted 10,302 shares, increasing direct ownership by 70% to 25,011 units (SEC Form 4)
- Director Klencke Barbara was granted 10,302 shares, increasing direct ownership by 52% to 29,974 units (SEC Form 4)
- Director Montgomery Alan Bruce was granted 10,302 shares, increasing direct ownership by 66% to 25,849 units (SEC Form 4)
- Director Ranieri Richard J was granted 10,302 shares, increasing direct ownership by 75% to 24,011 units (SEC Form 4)
- Director Simpson Todd E was granted 10,302 shares, increasing direct ownership by 75% to 23,988 units (SEC Form 4)
- Director Deshaies Raymond Joseph was granted 10,302 shares (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- Director Feigal Ellen sold $89,370 worth of shares (6,843 units at $13.06) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 12,340 units (SEC Form 4)